Rating: Sell — Conviction: High
Astera Labs executes superbly: Q2 2026 revenue rose 104% to $392.4mm, Q3 is guided to $540–560mm, and it holds $1.25bn of net cash. The problem is the price. At $356 the stock trades at ~359x FY2025 GAAP EBITDA (after stock comp) and above even the bull case, which has revenue reaching ~$7.5bn by 2030 at a 41% margin. One end customer was >70% of FY2025 revenue, compounding the duration risk.
Conviction tests (3a-v-c): T1 pass (Base −76.1% at +1pp, −73.6% at −1pp; Sell at both; Bull still −39.5% / −32.4%) · T2 pass (Gordon −88%, exit-multiple −62%; Sell on either) · T3 pass · T4 pass
The rule's High may overstate certainty: a five-year DCF can't fully credit the decade of AI growth the market is pricing.
Business overview
Astera Labs is a fabless chip company whose connectivity silicon moves data between accelerators, CPUs and memory inside AI servers and racks. The products are Aries PCIe/CXL retimers, Scorpio smart fabric switches (P-Series PCIe 6 and the X-Series 320-lane scale-up switch), Taurus Ethernet smart cable modules and Leo CXL memory controllers. In FY2025 one end customer took more than 70% of revenue and the top three about 86% (10-K). Earnings rest on three variables. The first is AI server and accelerator build volumes at that end customer. The second is Scorpio's ramp: the company says fabric switches become its largest product family in Q3 2026, a quarter early. The third is operating leverage on a fast-growing R&D base, with GAAP opex guided at $232–236mm for Q3 alone. SBC was $160.0mm in FY2025.
Competition
Of the competitors the 10-K names, Broadcom and Marvell matter most for switches and custom-accelerator connectivity, Credo in cables and retimers. Pressure would show first in gross margin (Q3 guide ~72%, down from 73.3% in Q2 as switches gain mix), then in next-generation socket awards at the largest customer. Competitors are growing as fast as Astera: Credo's revenue for the quarter to 2026-08-01 was $479.0mm, up 115% year on year (Credo Q1 FY2027 release), against Astera's 104% in Q2. The listed comparables are far cheaper: Credo trades at 71.4x trailing EV/EBITDA and 28.8x forward P/E, Marvell at 83.0x and 49.1x, and Broadcom at 32.1x and 19.8x.
Bull case
- Scorpio ramp — the X-Series 320-lane switch takes Q3 revenue up ~40% quarter on quarter, and P-Series ramps broadly in 2027, with UALink and NVLink Fusion adding sockets. Plays out if a second hyperscaler adopts Scorpio X in volume and revenue compounds 75%/45%/30% after 2026. Model: rev_growth
- Operating leverage — the GAAP operating margin rose from 21.6% in H1 2026 to ~29.5% implied by the Q3 guide. A larger revenue base on fixed R&D could carry the GAAP EBITDA margin past 40%. Plays out if gross margin holds near 72% as switches dominate the mix. Model: ebitda_margin
- Premium holds — the Amazon warrant, which vests with up to $6.5bn of purchases of switch, signal-conditioning and optical products, signals a multi-year commitment. That keeps a growth multiple well above Broadcom's at year five. Plays out if purchases track the warrant tranches and beta normalises toward 2.0. Model: exit_ev_ebitda, wacc
Bear case
- Duration at a 5.2% risk-free rate — at ~359x FY2025 EBITDA, almost all value lies beyond year five. CAPM on a peer-average beta of 2.3 gives a 16.7% cost of equity, and a de-rating toward chip peers is the base path. Plays out if the 10Y stays above 5% or AI leadership unwinds. Model: wacc, exit_ev_ebitda
- Single-customer concentration — more than 70% of FY2025 revenue came from one end customer. A platform transition, a second-source decision or a capex digestion there would stall growth outright, not trim it. Plays out if FY2027 growth slows to ~15% and revenue falls in 2028–29. Model: rev_growth
- Mix and pricing — switches carry lower gross margin than retimers, and Broadcom and Marvell compete for the same sockets. Q3 opex annualises to ~$0.9bn, which deleverages hard on flat revenue. Plays out if gross margin falls toward the mid-60s. Model: ebitda_margin
Valuation & balance sheet
| Metric (definition) | Current | Own history (range or 5y avg) | Peers | Source, as-of |
|---|---|---|---|---|
| EV/EBITDA (model basis: diluted mkt cap − cash & securities + warrant; GAAP EBITDA after SBC) | 359x FY2025 · ~228x LTM (est.) | n/a (listed since March 2024) | CRDO 71.4x · MRVL 83.0x · AVGO 32.1x (trailing, aggregator) | Model; stockanalysis 2026-10-01 |
| EV/Sales (aggregator, trailing) | 50.4x | n/a (unverified) | CRDO 24.4x · MRVL 25.0x · AVGO 18.8x | stockanalysis 2026-10-01 |
| Forward P/E (consensus) | 63.5x | n/a (unverified) | CRDO 28.8x · MRVL 49.1x · AVGO 19.8x | stockanalysis 2026-10-01 |
| FCF yield (TTM FCF / basic mkt cap) | 0.4% ($276.7mm) | FY2025: OCF $319.3mm − capex $37.5mm = $281.8mm | n/a | stockanalysis; Q4 2025 release |
Model-implied value range (from model-summary.json; generic module, Gordon-growth DCF and exit-EV/EBITDA DCF, midpoints): Bear $16.46 · Base $89.49 · Bull $227.48 per share, i.e. implied returns of −95.4% / −74.9% / −36.2% vs $356.42. These ranges show how the bull and bear drivers translate into value; they are not price targets. The price sits ~57% above the bull midpoint: the market pays for more than five years of 30–75% growth and 40%+ margins. The base 28x exit multiple is a ~92% de-rating from today's same-basis 359x. The methods differ widely (Base Gordon $41.96, exit $137.02): the exit method embeds the higher terminal multiple, is the fairer read for a business still growing at year five, and is still 62% below the price. One end customer is more than 70% of revenue, so I ran a tail sensitivity on the bear: FY2026 +105%, then −20%, −15%, −5% and +2%; EBITDA margin falling from 25% to 10–12%; NWC 15% of revenue; a 12x exit; and an 18.7% WACC. The bear midpoint falls to $7.15.
Balance sheet: not meaningful (net cash): $1,253.0mm of cash and securities at 2026-06-30, no funded debt, net leverage −7.0x FY2025 EBITDA. The February 2026 Amazon warrant (up to 3.26mm shares at $142.82) is carried as a $696.8mm claim at today's price, ~$3.80 a share. No ratings.
Model note: verified: LibreOffice recalculation matched all 3,206 formula cells. Unverified inputs: none. Assumptions without basis: none. No scenario CHECKs. WACC uses a peer-average beta of 2.3 (CRDO, MRVL, AVGO). That is a deliberate haircut from the own 3.78 aggregator beta, which covers only ~2.5 years and would give 24.1%. EBITDA is GAAP after SBC; NWC excludes prepaid items. The company guides one quarter ahead (Q3 GAAP EPS $0.87–0.92), so there is no annual EPS guide to test Base FY2026 EPS of $2.81 against; Q2 GAAP net income ($153.1mm) exceeded operating income on tax items, so reported GAAP EPS isn't comparable. Whether warrant shares sit in the diluted count is n/a (unverified); carrying them as a claim may double-count up to ~$3.80 a share.
Scenario stress test
Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).
| Scenario | Effect | Mechanism | Magnitude | Model Δ value vs Base ($/sh) |
|---|---|---|---|---|
| S1 Fast equity crash | − | Beta 3.78 on a ~359x multiple; de-risking hits the multiple, no operating channel | Med | −$18.35 |
| S2 Slow bear / recession | − | Hyperscaler capex cuts, supply-chain inventory digestion, a ~$1bn opex base deleverages. Transitory, so about half the permanent Base − Bear gap ($73.03) | High | −$39.45 |
| S3 Rapid rate shock | − | No debt; nearly all value beyond Y5 re-prices on discount rate and growth multiple | Med | −$19.06 |
| S4 Slow rate grind | − | Same channel, grinding | Low | −$7.92 |
| S5 Soft-landing cuts | + | Lower discount rate on a long-duration equity; capex intact | Med | +$11.19 |
| S6 Recession-driven cuts | − | Capex cuts and growth de-rating outweigh lower rates | Med | −$25.14 |
| S7a Credit liquidity shock | − | Net cash, no funding need; forced selling hits top-multiple equities | Med | −$11.01 |
| S7b Slow default cycle | − | Debt-funded neoclouds and data-centre developers lose financing, trimming second-tier AI demand | Med | −$13.07 |
| S8 Stagflation | − | Wafer, substrate and wage inflation plus higher real rates on a long-duration equity | Med | −$17.27 |
| S9a Dollar spike | − | USD pricing into Asian ODM supply chains; modest | Low | −$0.79 |
| S9b Dollar slide | 0 | No material effect, not modeled (USD pricing and costs) | Low | $0.00 |
| S10 Melt-up | + | AI-leadership, beta-3.8 name: momentum extends the multiple | Med | +$18.35 |
| S11 Energy supply shock | − | No direct cost channel; risk-off and rate pressure only | Low | −$3.67 |
| S12 Mega-cap/AI derating | − | The direct channel: AI-leadership unwind de-rates the multiple and trims connectivity orders | High | −$38.96 |
Currently active/on watch per the playbook: S3 partially active (10Y ≥5% price-level leg met); S8, S10, S11 on watch.
What would change the call
Upgrades if: the price falls toward the bull midpoint while Q3–Q4 deliver the Scorpio ramp with GAAP gross margin ≥72%, or a second hyperscaler is disclosed above 10% of revenue, cutting concentration below 50%. Downgrades if: n/a below Sell. The conviction weakens if Q4 guidance implies sequential deceleration below 10%, or if the 10-K shows the largest customer's share rising further.
Watch items
- W1: Q3 2026 revenue vs the $540–560mm guide, and the Q4 guide — a miss or flat Q4 guide breaks Base's ~$1.9bn FY2026 — Q3 earnings release — early November 2026 — Model: rev_growth
- W2: Largest end customer's share of FY2026 revenue vs >70% in FY2025 — FY2026 10-K — February 2027 — Model: rev_growth
- W3: GAAP gross margin as Scorpio becomes the largest family — below 70% for two quarters confirms bear #3 — Q3/Q4 releases — Model: ebitda_margin
- W4: Amazon warrant tranches vested (a proxy for purchases against the $6.5bn ceiling) — 10-Q equity note — November 2026 — Model: none
Sources
- Astera Labs (ALAB) statistics, stockanalysis.com — https://stockanalysis.com/stocks/alab/statistics/ — accessed 2026-10-02
- Credo, Marvell, Broadcom statistics, stockanalysis.com — https://stockanalysis.com/stocks/crdo/statistics/ · https://stockanalysis.com/stocks/mrvl/statistics/ · https://stockanalysis.com/stocks/avgo/statistics/ — accessed 2026-10-02
- SEC EDGAR XBRL companyconcept, revenue and operating income, CIK 1736297 — https://data.sec.gov/api/xbrl/companyconcept/CIK0001736297/us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax.json · https://data.sec.gov/api/xbrl/companyconcept/CIK0001736297/us-gaap/OperatingIncomeLoss.json — accessed 2026-10-02
- Astera Labs Q2 2026 earnings release (8-K ex. 99.1) — https://www.sec.gov/Archives/edgar/data/0001736297/000173629726000033/q226exhibit991.htm — accessed 2026-10-02
- Astera Labs Q4/FY2025 earnings release — https://www.sec.gov/Archives/edgar/data/1736297/000173629726000005/q425exhibit991.htm — accessed 2026-10-02
- Astera Labs Q4/FY2024 earnings release — https://www.sec.gov/Archives/edgar/data/1736297/000173629725000001/q424exhibit991.htm — accessed 2026-10-02
- Astera Labs FY2025 Form 10-K — https://www.sec.gov/Archives/edgar/data/1736297/000173629726000010/alab-20251231.htm — accessed 2026-10-02
- Astera Labs Form 8-K 2026-02-10 (Amazon warrant) — https://www.sec.gov/Archives/edgar/data/1736297/000110465926012606/tm265461d1_8k.htm — accessed 2026-10-02
- Credo Q1 FY2027 results (8-K ex. 99.1) — https://www.sec.gov/Archives/edgar/data/0001807794/000162828026059795/credoq12027ex-991.htm — accessed 2026-10-02
- logs/macro-2026-10.md, 2026-10-01 entry (10Y 5.24%) — accessed 2026-10-02